BMEA
Biomea Fusion, Inc.NASDAQHealthcare$1.54+3.36%ClosedMarket Cap: $91.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.69
P/S
0.00
EV/EBITDA
-0.46
DCF Value
$0.98
FCF Yield
-78.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-243.7%
ROA
-105.5%
ROIC
-170.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $4.6M | $0.06 |
| FY 2025 | $0.00 | $-61.8M | $-1.18 |
| Q3 2025 | $0.00 | $-16.4M | $-0.27 |
| Q2 2025 | $0.00 | $-20.7M | $-0.51 |
Analyst Ratings
View AllCitigroupBuy
2026-03-27D. Boral CapitalBuy
2026-03-25D. Boral CapitalBuy
2026-01-13CitigroupBuy
2025-11-10D. Boral CapitalBuy
2025-11-05Trading Activity
Insider Trades
View AllErdtmann Rainer Mdirector, officer: See Remarks
SellFri Apr 03
Hitchcock Michael J.M.director, officer: Interim CEO
SellFri Apr 03
Erdtmann Rainer Mdirector, officer: See Remarks
SellFri Feb 06
Erdtmann Rainer Mdirector, officer: See Remarks
BuyMon Dec 15
Hitchcock Michael J.M.director, officer: Interim CEO
BuyThu Dec 04
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.27
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.